An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based ...

New study supports use of hormone therapy followed quickly by immunotherapy for prostate cancers, which are largely resistant ...

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) recommends shorter courses of radiation ...

Talzenna-Xtandi secures an FDA label expansion as the cancer treatment paradigm shifts towards the use of mutation-specific ...

Darolutamide improved metastasis-free survival alongside hormone therapy and radiotherapy in very high-risk prostate cancer.

Yesterday, the United States Food and Drug Administration (FDA) announced the approval of a new immune-based approach for ...

(n=6) remain disease-free more than two years after treatment; 80% of patients treated with SYNC-T Therapy SV-102 (n=15) alive at ...

A large integrated transcriptomic study shows that rising cancer stemness tracks prostate cancer progression, lineage ...

A new review finds that rare prostate cancer histologies, which make up less than 5% of cases, are aggressive, often missed ...

The Decipher genomic test could help doctors decide which high-risk prostate cancer patients need abiraterone hormone therapy ...